Opinion

Video

Real-World Impact of SUNLIGHT Outcomes in mCRC

Medical experts discuss key takeaways from the SUNLIGHT trial, which compared FTD/TPI monotherapy to FTD/TPI plus bevacizumab for advanced metastatic colorectal cancer, including overall survival, safety, and benefits regardless of prior bevacizumab therapy, and how this data has influenced the use of FTD/TPI in the third-line setting compared with real-world outcomes.

  • The recent SUNLIGHT trial compared FTD/TPI monotherapy to FTD/TPI in combination with bevacizumab for advanced metastatic colorectal cancer. Describe the key takeaways from this trial.
  • Include in your discussion overall survival, safety profile, as well as benefit seen regardless of prior bevacizumab therapy.
  • How has the SUNLIGHT data impacted your overall use of FTD/TPI in the third-line setting?
  • How do the outcomes in SUNLIGHT compare with what you’ve seen as real-word outcomes?
Related Videos
Parth Rali, MD
1 KOL is featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo